Photo of Hanna Irie

Hanna Irie

  • ASSISTANT PROFESSOR Medicine, Hematology and Medical Oncology
  • ASSISTANT PROFESSOR Oncological Sciences
Print ProfilePrint Profile


  • Medical Oncology

Clinical Focus


  • American Board of Internal Medicine


  • MD/PHD, Harvard Medical School

  • M.D., Harvard Medical School

  • Research Fellow, Harvard Medical School

  • Instructor, Dana-Farber Cancer Institute/Harvard Medical School

  • Clinical Fellow, Dana-Farber Cancer Institute

  • Intern/Resident, Massachusetts General Hospital

  • B.A., Harvard University

  • Ph.D., Harvard Medical School

  • Residency, Internal Medicine
    Massachusetts General Hospital

  • Fellowship, Hematology/Oncology
    Dana Farber Cancer Institute


    I am a medical oncologist specializing in the care of patients with breast cancer. As a physician-scientist, I also lead a research laboratory that is focused on developing targeted therapies tailored for specific breast cancer subtypes and for individual patients. I have a particular interest in better understanding triple negative breast cancers, with the goal of integrating genetic analysis to the development of improved treatments for our patients.

    I am co-PI of the Breast Tumor Biospecimen Repository, which is a bank of patient breast tumors; analysis of these tumors will provide insights into the genetic changes that determine sensitivity to specific targeted therapies for breast cancer. I am also co-PI of a study investigating the use of patient-derived xenograft models as a model for chemotherapy treatment sensitivity for patients with triple negative breast cancers; if successful, these models may be used in the future to help us better tailor treatments for individual patients. My research laboratory has identified several new candidate therapeutic targets for Her2+ and triple negative breast cancers resistant to current treatments, and we are working to translate our findings to clinical studies and trials.

    I am a member of the American Society of Clinical Oncology and the American Association for Cancer Research.





  • 2015 - 2016
    Breast Cancer Alliance Exceptional Project Grant
    Breast Cancer Alliance

  • 2014 - 2015
    Breast Cancer Research Foundation Grant
    Breast Cancer Research Foundation

  • 2013 - 2015
    AACR-Genentech BioOncology Career Development Award for Research on the Her Family in Cancer

  • 2012 - 2015
    Susan G Komen Career Catalyst Award
    Susan G Komen for the Cure

  • 2009 - 2010
    Dana Farber Cancer Institute SPORE in Breast Cancer Career Development Award

  • 2008 - 2009
    Terri Brodeur Breast Cancer Research Foundation Grant
    Terri Brodeur Breast Cancer Research Foundation

  • 2006 - 2006
    AACR Scholar-in-Training Award
    American Assocaition for Cancer Research

  • 2006 - 2012
    K08 Mentored Clinical Scientist Award

  • 2004 - 2004
    ASCO Young Investigator Award
    American Society for Clinical Oncology


Ravichandran KS, Pratt JC, Sawasdikosol S, Irie HY, Burakoff SJ. Coreceptors and adapter proteins in T-cell signaling [review]. Annals of the New York Academy of Sciences 1995 Sep; 766.

Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. The Journal of cell biology 2005 Dec; 171(6).

McKay DB, Irie HY, Hollander G, Ferrara JL, Strom TB, Li Y, Burakoff SJ. Antigen-induced unresponsiveness results in altered T cell signaling. Journal of immunology (Baltimore, Md. : 1950) 1999 Dec; 163(12).

Irie HY, Jaklitsch MT, Shaffer K, Weinstein M, Salgia R. Unusual problems in breast cancer and a rare lung cancer case. Case 4. Primary lymphoepithelioma-like carcinoma of the lung. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Jun; 21(11).

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer research 2005 Dec; 65(23).

Irie HY, Mong MS, Itano A, Crooks ME, Littman DR, Burakoff SJ, Robey E. The cytoplasmic domain of CD8 beta regulates Lck kinase activation and CD8 T cell development. Journal of immunology (Baltimore, Md. : 1950) 1998 Jul; 161(1).

Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. A CD8/Lck transgene is able to drive thymocyte differentiation. Journal of immunology (Baltimore, Md. : 1950) 2006 Nov; 177(9).

Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009 Sep; 461(7260).

Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PloS one 2010; 5(7).

Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, Irie HY, Connolly JL, Schnitt SJ. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast cancer research and treatment 2011 Jul; 128(1).

Irie HY, Ravichandran KS, Burakoff SJ. CD8 beta chain influences CD8 alpha chain-associated Lck kinase activity. The Journal of experimental medicine 1995 Apr; 181(4).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Irie during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.



Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Annenberg Building Floor 24 Room 04D
1468 Madison Avenue
New York, NY 10029

Dubin Breast Center

1176 Fifth Avenue
First Floor
New York, NY 10029

Tel: 212-241-3300
Fax: 212-289-0678
Get Directions
Insurance Plans
  • 1199
  • Access Medicare
  • Aetna
  • Affinity
  • Amerigroup
  • AmidaCare
  • Cigna - HMO
  • Empire Blue Cross/Blue Shield - PPO
  • Fidelis Medicare
  • GHI
  • Health Insurance Plan (HIP)
  • HealthFirst
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Oxford Health Plans
  • Pomco
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash